Melinta Therapeutics Announces Appointment of Susan Blum as Main Financial Officer
MORRISTOWN, N.J., June 29, 2021–(Enterprise WIRE)–Melinta Therapeutics, LLC (“Melinta”), a business-phase business delivering ground breaking therapies for acute and existence-threatening ailments, announces the appointment of Susan Blum as Chief Economic Officer, efficient July 1, 2021.
Ms. Blum has served as Melinta’s interim CFO, less than the leadership of President and Main Govt Officer Christine Ann Miller, because March 31, 2021, and she has been an integral leader on Melinta’s finance and accounting teams since 2016. Ms. Blum has a demonstrated monitor file of strengthening and executing company financial method, efficiencies and controls for Melinta as perfectly as varied corporations prior to Melinta.
“Susan is a seasoned finance executive and our dependable companion, with extensive knowledge about our enterprise, products and markets. I’m the two proud and enthusiastic to welcome her as our CFO to aid guide our enterprise ahead with sustainable expansion,” Ms. Miller stated. “As we keep on to create a famous foreseeable future, her encounter, as effectively as her enthusiasm and determination to Melinta, will be an extraordinary asset.”
Prior to joining Melinta, Ms. Blum held leadership positions in finance and accounting at Textura, Orbitz Around the globe, Facet Biotech and PDL BioPharma. In these roles, some of her notable encounter consists of directing international economical processes, main accounting features through dynamic organization situations, which include preliminary and secondary community choices, and directing economical reporting and integration pursuits for mergers and acquisitions.
“I’m honored to guide Melinta’s fiscal workforce and functions at this enjoyable instant in the company’s journey,” Ms. Blum explained. “Melinta is genuinely unparalleled in enthusiasm and intent, and I’m enthusiastic to go on to perform with Christine and the rest of the workforce towards money sustainability although being grounded in what issues most — the patients we provide.”
About Melinta Therapeutics
Melinta Therapeutics, LLC delivers innovative therapies to folks impacted by acute and everyday living-threatening ailments. Our portfolio at present includes five commercial-stage antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to suppliers and the clients they provide, we operate to make sure that all people who need our therapies can get them. We target our increasing portfolio on serving sufferers with an unmet need due to the fact which is how we make the most significant affect. At Melinta, we’re visionaries focused to innovation though keeping grounded in what issues most: patients. Pay a visit to www.melinta.com for much more facts.
See supply model on businesswire.com: https://www.businesswire.com/news/home/20210629005251/en/
Contacts
Kristen Allgor
+1 312 767-0296
[email protected]
